Insights on the Antimicrobial Efficacy of Azithromycin According to the First Croatian Antibiotic Susceptibility Study of Chlamydia Trachomatis Isolates from Genitourinary Tract
APA 6th Edition Meštrović, T. i Ljubin-Sternak, S. (2018). Spoznaje o antimikrobnoj djelotvornosti azitromicina sukladno prvomu hrvatskom istraživanju antibiotske osjetljivosti klamidijskih izolata iz mokraćno-spolnog sustava. Medicus, 27 (2 Sumamed), 177-182. Preuzeto s https://hrcak.srce.hr/214612
MLA 8th Edition Meštrović, Tomislav i Sunčanica Ljubin-Sternak. "Spoznaje o antimikrobnoj djelotvornosti azitromicina sukladno prvomu hrvatskom istraživanju antibiotske osjetljivosti klamidijskih izolata iz mokraćno-spolnog sustava." Medicus, vol. 27, br. 2 Sumamed, 2018, str. 177-182. https://hrcak.srce.hr/214612. Citirano 05.12.2019.
Chicago 17th Edition Meštrović, Tomislav i Sunčanica Ljubin-Sternak. "Spoznaje o antimikrobnoj djelotvornosti azitromicina sukladno prvomu hrvatskom istraživanju antibiotske osjetljivosti klamidijskih izolata iz mokraćno-spolnog sustava." Medicus 27, br. 2 Sumamed (2018): 177-182. https://hrcak.srce.hr/214612
Harvard Meštrović, T., i Ljubin-Sternak, S. (2018). 'Spoznaje o antimikrobnoj djelotvornosti azitromicina sukladno prvomu hrvatskom istraživanju antibiotske osjetljivosti klamidijskih izolata iz mokraćno-spolnog sustava', Medicus, 27(2 Sumamed), str. 177-182. Preuzeto s: https://hrcak.srce.hr/214612 (Datum pristupa: 05.12.2019.)
Vancouver Meštrović T, Ljubin-Sternak S. Spoznaje o antimikrobnoj djelotvornosti azitromicina sukladno prvomu hrvatskom istraživanju antibiotske osjetljivosti klamidijskih izolata iz mokraćno-spolnog sustava. Medicus [Internet]. 2018 [pristupljeno 05.12.2019.];27(2 Sumamed):177-182. Dostupno na: https://hrcak.srce.hr/214612
IEEE T. Meštrović i S. Ljubin-Sternak, "Spoznaje o antimikrobnoj djelotvornosti azitromicina sukladno prvomu hrvatskom istraživanju antibiotske osjetljivosti klamidijskih izolata iz mokraćno-spolnog sustava", Medicus, vol.27, br. 2 Sumamed, str. 177-182, 2018. [Online]. Dostupno na: https://hrcak.srce.hr/214612. [Citirano: 05.12.2019.]
Sažetak Regardless of the fact that antimicrobial resistance represents one of the most pressing issues of modern medicine, thus far chlamydial infection responded well to the first-line therapy i.e. azithromycin. Nonetheless, laboratory-confirmed resistance of sexually-transmitted pathogen Chlamydia trachomatis (C. trachomatis) causing this infection has been repeatedly described in the literature; furthermore, Croatia belongs to the group of countries that exhibit high prescribing rates of azithromycin and other antimicrobial drugs, which can, in turn, give rise to frank resistance or decreased susceptibility. Accordingly, the first Croatian antibiotic susceptibility study of Chlamydia trachomatis aimed to assess in vitro effectiveness of azithromycin and other antibiotics against clinical chlamydial isolates from genitourinary tract. McCoy cell culture model was used to assess minimal inhibitory concentration (MIC) and minimal chlamydicidal concentration (MCC), and all the tested isolates were susceptible to azithromycin (MIC < 4 μg/ml). Although no resistant strains have been found, certain isolates showed significantly higher values of MCC for azithromycin, pointing towards the trend of possible decreased susceptibility. Regardless of the complex methodology, it is pivotal to continue with this kind of resistance surveillance, especially in countries with high antibiotic prescribing rate.